KPTI Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc (KPTI) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $20.9K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Abate Kristin | Chief Accounting Officer | Sell | 19 | $2.02 | $38 | 23,782 −0.1% of holding | |
| Poulton Stuart | EVP, Chief Development Officer | Sell | 189 | $7.10 | $1.3K | 94,632 −0.2% of holding | |
| Paulson Richard A. | President and CEO | Sell | 2,203 | $9.50 | $20.9K | 269,747 −0.8% of holding | |
| Rangwala Reshma | EVP & Chief Medical Officer | Sell | 408 | $9.50 | $3.9K | 56,829 −0.7% of holding | |
| Poulton Stuart | EVP, Chief Development Officer | Sell | 403 | $9.50 | $3.8K | 94,821 −0.4% of holding | |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer | Sell | 324 | $9.50 | $3.1K | 107,940 −0.3% of holding | |
| Mano Michael | EVP, CLO&Secretary | Sell | 266 | $9.50 | $2.5K | 94,398 −0.3% of holding | |
| Abate Kristin | Chief Accounting Officer | Sell | 53 | $9.50 | $504 | 23,801 −0.2% of holding | |
| Rangwala Reshma | EVP & Chief Medical Officer | Sell | 449 | $8.94 | $4.0K | 56,290 −0.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.